Gynecology PGx.
Information for your treatment plan. A gene panel for medications used in gynecologic and reproductive health care, including flibanserin and ospemifene. One saliva sample, run in our CLIA-certified lab, with results your prescriber can refer back to.
- One sample, no blood draw
- Results in 3–7 business days
- Share with any prescriber
Panel
2 genes · CYP2C19, CYP3A4
Sample
Saliva or cheek swab
Results
3–7 business days
Price
From $289
What we test
Panel medications.
See how your genes may affect your response to certain medications. Review your results with your prescriber.
Flibanserin — CYP2C19
Poor CYP2C19 metabolizers reach higher flibanserin levels, which raises the risk of low blood pressure, fainting and sedation.
Ospemifene — CYP3A4
CYP3A4 metabolism determines how this dyspareunia therapy is cleared.
Who this is for
Differences in drug metabolism can change how well a treatment works and how well it is tolerated.
Considering these medications
Testing before starting flibanserin or ospemifene puts the safety picture in place first.
A previous treatment failed
Side effects or no benefit from a reproductive-health medication may be a metabolism question.
Other medications on board
CYP2C19 and CYP3A4 handle many common drugs — interactions are worth knowing in advance.
Is this test right for you?
You are considering flibanserin or ospemifene.
A previous treatment caused side effects or did not help.
You want to understand how you process related medications.
You take other medications that may interact.
Your gynecologist suggested genetic testing.
You want results you can keep for future prescriptions.
Answering yes to even one of these is a good reason to test before the next prescription change.
Before you order
Total price
From $289
One-time price, shown in full at checkout before you pay. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
A saliva or cheek-swab kit with instructions, a prepaid return label, the healthcare provider order, genetic testing in our lab and a gene-drug report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
When to expect results
3–7 business days
After the lab receives your sample. You are notified as soon as your report is in your secure portal.
The science
What the evidence says about getting tested.
Flibanserin is cleared almost entirely by CYP2C19, and its own FDA labeling says poor metabolizers reach roughly twice the drug exposure — which is why the label calls out CYP2C19 status and drug interactions directly. Ospemifene depends on CYP3A4, the enzyme that clears about half of all oral medications, so co-prescribed drugs and inherited differences both change exposure. Two genes cover both stories.
≈2×
flibanserin exposure in CYP2C19 poor metabolizers compared with normal metabolizers.
Source: FDA flibanserin labeling
Up to 1 in 5
of people of East Asian ancestry are CYP2C19 poor metabolizers — the group with the highest flibanserin exposure.
Source: CYP2C19 pharmacogenetics literature
About half
of oral medications are cleared by CYP3A4, so interactions and inherited differences both matter for ospemifene.
Source: Pharmacokinetics reviews
≈4%
of European populations carry the CYP3A4*22 reduced-function allele, which can slow drug clearance.
Source: CYP3A4*22 pharmacogenetics literature
How often should you test?
Test once — your genotype doesn't change. The highest-value moment is before starting flibanserin or ospemifene, especially if you take other medications, drink alcohol, or have had low blood pressure or fainting with any medication before.
References
- U.S. National Library of Medicine, DailyMed — flibanserin prescribing information: CYP2C19 poor-metabolizer exposure and contraindicated interactions.
- U.S. National Library of Medicine, DailyMed — ospemifene prescribing information: CYP3A4 metabolism and interactions.
- PubMed literature — CYP2C19 metabolizer status and flibanserin exposure.
- PubMed literature — CYP3A4*22 reduced-function allele and drug clearance.
Population data
How common is each metabolizer type?
Published population frequencies for the cytochrome P450 enzymes read on this panel. Your report places you in one of these groups for each enzyme.
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
|---|---|---|---|---|
| CYP2D6 | 4–7% | 9–35% | 50–90% | 2–3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19 | 2–20% | 24–36% | 14–44% | 30% |
Population frequencies compiled from CPIC guidelines and FDA pharmacogenomic biomarker tables; frequencies vary by ancestry.
Questions people actually ask
Bring data to your next appointment.
One sample, one flat price, a report your prescribers can refer back to.